JP4038088B2 - Muscle protein degradation inhibitor - Google Patents

Muscle protein degradation inhibitor Download PDF

Info

Publication number
JP4038088B2
JP4038088B2 JP2002221242A JP2002221242A JP4038088B2 JP 4038088 B2 JP4038088 B2 JP 4038088B2 JP 2002221242 A JP2002221242 A JP 2002221242A JP 2002221242 A JP2002221242 A JP 2002221242A JP 4038088 B2 JP4038088 B2 JP 4038088B2
Authority
JP
Japan
Prior art keywords
lycopene
muscle
protein degradation
muscle protein
blood
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2002221242A
Other languages
Japanese (ja)
Other versions
JP2004059518A (en
Inventor
英一郎 一石
渉 青井
柾樹 小林
俊二 大嶋
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kagome Co Ltd
Original Assignee
Kagome Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kagome Co Ltd filed Critical Kagome Co Ltd
Priority to JP2002221242A priority Critical patent/JP4038088B2/en
Publication of JP2004059518A publication Critical patent/JP2004059518A/en
Application granted granted Critical
Publication of JP4038088B2 publication Critical patent/JP4038088B2/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23KFODDER
    • A23K50/00Feeding-stuffs specially adapted for particular animals
    • A23K50/20Feeding-stuffs specially adapted for particular animals for horses

Description

【0001】
【発明の属する技術分野】
この発明は、ヒトその他の動物の筋タンパク質分解の抑制効果があり、化粧品、医薬品などに用いられる筋蛋白分解抑制剤に関する。
【0002】
【従来の技術】
一般に、マラソンなどのように長時間に及ぶ激しい筋肉運動をした後は、筋肉内のグリコーゲンが減っており、また血糖も下がり気味であるので、この状態を放置すると、筋肉の蛋白質が分解されることにより、体内のエネルギー不足を補うことになってしまうことが知られている。
【0003】
また、ヒトその他の動物は、老化してくると血中にグルココルチコイドという蛋白質の分解を促進し、またその合成を抑制する老化ホルモンが増えてくることが知られている。
【0004】
いずれの場合も健康な骨格筋が、体内の恒常作用の弊害によって分解され、別言すれば筋肉が損傷する場合があり、これをできるだけ防止できる機能性飲食品や化粧品、医薬品などが要望されている。
【0005】
通常、筋肉の分解を抑制するには、良質の蛋白質を多く摂取することが常識であり、例えばグルタミンや分岐アミノ酸の一種は、蛋白分解作用を抑制することが知られている。
【0006】
一方、リコピンは抗酸化作用のある物質として多くの生物に存在し、動物においては血中濃度が寿命と関係することがアメリカのカトラー博士(Cutler, Proc.Natl.Acad.Sci.USA,81(1984))により報告されている。
【0007】
【発明が解決しようとする課題】
しかし、上記した従来技術では、生体におけるリコピンの抗酸化作用として、生体中の活性酸素の中和作用は知られているが、リコピンが運動時の筋肉量に関与する物質であるか否かは知られていない。
【0008】
また、筋肉の分解を抑制するには、グルタミンや分岐アミノ酸の一種を用いるが、これらは筋肉の生成量を高めて相対的な蛋白分解抑制を行なうものであり、直接に筋肉の分解を抑制する物質を有効成分とする薬剤が要望されていた。
【0009】
そこで、この発明の課題は、上記した問題点を解決して、ヒトその他の動物の筋タンパク質分解の抑制に直接にかつ効率よく作用し、しかも副作用のない筋蛋白分解抑制剤およびこれを用いた筋損傷検査方法および機能性飲食品とすることである。
【0010】
【課題を解決するための手段】
上記の課題を解決するために、この発明においては、リコピンを有効成分として含有する筋蛋白分解抑制剤としたのである。
【0011】
上記したように構成されるこの発明の筋蛋白分解抑制剤は、トマトや西瓜などに含有されている優れた脂溶性の抗酸化プロビタミンであるリコピンを有効成分としており、リコピンを所定量摂取することにより筋蛋白分解を高い安全性の下で予防できる。
【0012】
また、成人に対する有効成分量が、60mg以上/日である上記の筋蛋白分解抑制剤とすることが好ましい。
【0013】
また、リコピンを有効成分として食品や化粧品、医薬品などに使用することにより、副作用なく筋タンパク質分解を抑制することが可能である。
【0014】
そして、本願の発明者らは運動時に必要なリコピンの量を知ることや、リコピンを適当な時期に投与することが高齢者の筋肉増強や運動選手の筋肉疲労改善に役立つことを発見したのである。
【0017】
【発明の実施の形態】
この発明に用いるリコピンは、1903年に、C.A.Schunkによってリコピンと命名された脂溶性のカロチノイド(分子量537)の一種であり、β-カロチンのように体内でビタミンAには変わらないので、プロビタミンとも呼ばれるが、このものは強い抗酸化作用がある。
【0018】
リコピンを多く含む代表的な食品は、トマトであり、それ以外ではスイカや柿、ルビー系グレープフルーツなどにも含まれる。また、トマトの中でも、特に赤系トマトに多く含まれている。リコピンの含有量は、品種によって大きく異なるが、例えばミニトマトでは、100g当たり7〜11mgという知見がある。
【0019】
また、このようなリコピンを筋蛋白分解抑制剤として作用させる場合には、その有効成分量を用いる。それは後述の実験結果からも明らかであるが、体重280gのラットに対して、リコピンを1日10mg以上与えれば筋タンパク質の分解が抑制できるという結果を、遺伝学的にラットの筋組織と相違の無いヒトに対しても応用できる。
【0020】
ラットとヒトの体内挙動は異なるが、ラットと同肝臓濃度でヒトでも効果があると推定される。そして、ラット肝臓中のリコピン濃度が3.4μg/mlで筋蛋白分解抑制効果があり、またヒト肝臓中のリコピン濃度は、血清濃度の4.4倍である(Stahl et al.Archm.Biophys.,297,173-177)との知見から、ヒト血清濃度が3.4/4.4=0.77μg/mlで筋蛋白分解抑制効果があると考えられる。
【0021】
ここで、正常なヒト血清リコピン濃度は、100〜200ng/mlであり、筋蛋白分解抑制のためにヒト血清リコピン濃度を上昇させるための摂取量は、血清濃度上昇試験の結果からその4〜8倍量である。
【0022】
このように上記の見解から算出されるヒト(成人)の有効摂取量は、およそ60mg以上/日である。
【0023】
強度の運動を行う場合においては、健常人に対して一日当り60mg以上のリコピンを適宜に経口で摂取させることにより、運動時の筋蛋白分解を予防できる。また、リコピンを食品、化粧品、医薬品に投与することにより筋蛋白の分解を予防することができる。
【0024】
また、リコピンは、トマトや西瓜に含有される脂溶性の抗酸化プロビタミンとして経口で服用できることが知られているが、この抗酸化性の効果を期待しリコピンを1日60mg以上/日摂取すると、筋蛋白分解を予防することに有効である。
【0025】
また、リコピンを有効成分とする筋蛋白分解抑制剤の投与量および投与回数は、上記した一日当りの有効量を摂取できるならば複数回に分けて摂取させることは、吸収効率から見ても好ましく、例えば3〜5回に分けて各所定分量を摂取することはより好ましいことである。
【0026】
筋蛋白分解抑制剤を摂取することにより、筋損傷を予防するには、血中リコピン濃度100〜200ng/mlを正常範囲として、この範囲未満の検査値である場合に筋蛋白分解抑制剤を摂取することが効果的である。
【0030】
筋損傷の予防検査を行なうには、血中リコピン量の測定ばかりでなく、血中CPK、血中LDH、血中グルココルチコイド、血中TNFα、尿中3−メチルヒスチジン(クレアチン比)、筋中グルココルチコイドレセプター含量、筋中TNFα含量、筋中酸化生成物(4HNE、TBARSや8OHdGなど)の検査を行うことが好ましく、特に、筋損傷の有無を調べる検査を行うにはこれらの検査が必要である。
【0031】
【実施例】
運動時におけるリコピンの必要性の有無と、必要量を調べる方法として、9週齢SD系雌ラットを1週間予備飼育した後、普通食安静群、普通食運動負荷群、およびリコピン運動負荷群の3群に分けた。
【0032】
リコピン摂取時には普通食100g当り50mgのリコピンを混合し、これを自由に摂食させた。運動負荷群には比較的高強度なトレッドミルランニング運動を負荷した。
【0033】
トレッドミルランニング運動条件は、傾斜角度なしで15m/分、20分ランニングさせ、傾斜角度5度で26m/分で引き続き20分ランニングさせ、強度と運動時間を2週間漸増させた。
【0034】
最終運動を負荷してから24時間尿を採取した後に屠殺し、腓腹筋、肝臓及び血液を採取した。
<筋蛋白分解抑制効果の検査>
検査項目は、筋肉損傷度を血清CPK(クレアチンフォスフォキナーゼ)、肝機能損傷度を血清GOT(グルタミン酸オキザロ酢酸転換酵素)、脂質酸化状態を血清過酸化脂質、筋タンパク分解度を尿中3−メチルヒスチジン(クレアチニン比)、TNFα、グルココルチコイドレセプター1を測定した。また、腓腹筋と肝臓の組織中のリコピン濃度を測定した。
【0035】
【表1】

Figure 0004038088
【0036】
<運動時のリコピン摂取効果>
筋肉損傷マーカーであるCPKやGOTは、安静時と比較して、各運動群では変動が観察されなかった。しかし、筋タンパク分解度を調べるマーカーである尿中3−メチルヒスチジンや血中TNFαと血中グルココルチコイドレセプター1がリコピンを添加した食事を摂取した群は、安静群と比較して低値であり、この成績から、リコピンが筋蛋白分解抑制の効果のあることが認められた。
【0037】
また、上記の試験結果から、リコピンを食品に添加すると、筋蛋白分解抑制の効果について有効であり、また、リコピンを化粧品の原料素材や医薬品に用いることにより、筋蛋白分解抑制の効果があると認められる。
【0038】
また、9週齢ラット体重280gに対して、リコピンを1日10mg以上与えれば筋タンパク質の分解が抑制できるということは、遺伝学的に筋組織に相違が無いヒトに対しても応用できることであり、体重比較からリコピン含有の飲食品、化粧品、医薬品に所要量を投与することで筋蛋白の分解を予防できる。
【0039】
すなわち、強度の運動を行う場合のすべての場合において、健常人に対して一日当り60mg以上のリコピンを経口により常時摂取することにより運動時の筋蛋白分解を予防できるのである。
【0040】
具体的には、リコピンはトマトや西瓜に含有される脂溶性の抗酸化プロビタミンであり、飲用もなされているが、リコピンを有効成分として1日60mg以上摂取すると、筋蛋白分解を予防できる。
【0041】
また、筋損傷の有無を検査する場合において、血中CPK、血中LDH、血中グルココルチコイド、血中TNFα、尿中3−メチルヒスチジン(クレアチン比)、筋中グルココルチコイドレセプター含量、筋中TNFα含量、筋中酸化生成物(4HNE、TBARSや8OHdGなど)の項目が必要であることが確認できた。
【0042】
図1を用いて説明すると、まず被験者に対して、尿中の3−メチルヒスチジン(クレアチン比=C)を測定し、それをS(=標準)値と比較する。
【0043】
S(=標準)値は、予め多くの健常者から採取された尿から測定されたクレアチン比の平均値であり、例えば24時間尿中に3−メチルヒスチジン100μmol、クレアチニン1.0gが***されたとすると100μmol/gr Cre/dayという値を採用できる。
【0044】
次に、C≦Sの結果である場合には、筋損傷が全く起こっていないと認められるので、このまま筋肉の強化運動を継続して行なう判定をすることができる。
【0045】
一方、C>Sの結果である場合には、筋損傷が起こっている可能性があるため、血中リコピン値を測定する。
【0046】
血中リコピンを定量的に測定するには、以下のように行なった。
【0047】
まず、血清0.2mlにエタノール1.0mlを添加した後、ヘキサン、ジクロロメタンを4:1(容量比)の混合溶媒5mlを加えて攪拌した。これを遠心した後に上清を取り出し、ここまでの工程をもう一度繰り返して行なった。
【0048】
得られた上清を減圧下に濃縮し、乾燥させて固化し、これに溶媒0.2mlを加えて溶解し、紫外部または可視部吸収検出器(測定波長460nm、検出感度20ng/ml)または電気化学検出器(検出感度0.1ng/ml)を用いて高速液体クロマトグラム法(HPLC分析)にて血中リコピン値を測定した。
【0049】
この結果による血中リコピン値が正常値(100〜200ng/ml)である場合には、さらにTNFα値やグルココルチコイドレセプター1の測定を行なって、さらに精密に判定することが好ましい。このとき、尿中3−メチルヒスチジンと血中リコピン濃度の推移を見ながら強化運動の程度を調整することが望ましい。
【0050】
また、血中リコピン値が、正常値未満の低い値である場合には、リコピン含有食品(前述のトマト、スイカ、柿など)を多く摂取するように栄養指導を行なうと共に、必要に応じて上述の筋蛋白分解抑制剤を摂取させる。
【0051】
このようにして、運動と筋蛋白分解度を検査し、筋蛋白分解抑制剤を摂取させ、またはリコピンやリコピンを有効成分とする食品、化粧品、医薬品を用いた商品を健康に役立てることができる。
【0052】
また、前述の筋損傷検査方法をビジネスシステムとして実施すると、競走馬の筋蛋白分解度を筋分解マーカーで検査し、異常値を示した場合にリコピンを飼料に添加し、筋肉の破壊を予防することができる。
【0053】
また、養殖魚の飼料にリコピンを添加し、筋肉分解度やリコピン濃度を測定することで、予め筋損傷を予防できるから、魚の旨みを逃さずに流通させて、美味しい魚を消費者まで届けることも可能である。
【0054】
また、高齢者の筋肉増強については、運動することで骨を増強し、骨粗しょう症をはじめ骨代謝異常の予防や痴呆・寝たきり老人を予防する効果を期待することができる。
【0055】
【発明の効果】
この発明は、以上説明したように、リコピンを有効成分として含有する筋蛋白分解抑制剤としたので、ヒトその他の動物の筋タンパク質分解の抑制に直接に効率よく作用し、しかも副作用のない筋蛋白分解抑制剤であるという利点がある。
【0057】
また、血中リコピン濃度の所定域を境界値として、この範囲未満と判定された場合に、筋肉の健康状態を把握して前記筋蛋白分解抑制剤を摂取させることにより、筋蛋白に損傷のない良好な健康状態を維持できる。
【図面の簡単な説明】
【図1】筋損傷予防方法の実施例を説明するフローチャート[0001]
BACKGROUND OF THE INVENTION
The present invention has the effect of suppressing muscle protein degradation in humans and other animals, cosmetics, it relates to muscle protein degradation inhibitor used for such medicines.
[0002]
[Prior art]
In general, after a long period of intense muscle exercise such as marathon, the amount of glycogen in the muscle has decreased and the blood sugar has also decreased, so if this state is left as it is, the muscle protein will be degraded. This is known to compensate for the lack of energy in the body.
[0003]
In addition, it is known that when humans and other animals age, aging hormones that promote the degradation of a protein called glucocorticoid in the blood and suppress its synthesis increase.
[0004]
In any case, healthy skeletal muscles are decomposed due to the adverse effects of homeostatic action. In other words, muscles may be damaged. Functional foods, cosmetics, pharmaceuticals, etc. that can prevent this as much as possible are required. Yes.
[0005]
In general, in order to suppress muscle degradation, it is common sense to consume a large amount of high-quality protein. For example, glutamine and one kind of branched amino acid are known to inhibit proteolytic action.
[0006]
On the other hand, lycopene is present in many organisms as an antioxidant substance, and in animals, blood concentration is related to life span. Dr. Cutler, Proc. Natl. Acad. Sci. USA, 81 ( 1984)).
[0007]
[Problems to be solved by the invention]
However, in the above-described prior art, the neutralizing action of active oxygen in the living body is known as the antioxidant action of lycopene in the living body, but whether or not lycopene is a substance involved in muscle mass during exercise. unknown.
[0008]
In addition, glutamine and a type of branched amino acid are used to suppress muscle degradation, but these increase the amount of muscle produced and inhibit relative proteolysis, directly suppressing muscle degradation. There has been a demand for a drug containing a substance as an active ingredient.
[0009]
Accordingly, an object of the present invention is to solve the above-described problems, and to use a muscle protein degradation inhibitor that acts directly and efficiently on the suppression of muscle protein degradation in humans and other animals and has no side effects. It is supposed to be a muscle damage inspection method and a functional food or drink.
[0010]
[Means for Solving the Problems]
In order to solve the above problems, in the present invention, a muscle protein degradation inhibitor containing lycopene as an active ingredient is used.
[0011]
The muscle protein degradation inhibitor of the present invention configured as described above contains lycopene, which is an excellent fat-soluble antioxidant provitamin contained in tomatoes, etc., as an active ingredient, and takes a predetermined amount of lycopene Therefore, muscle protein degradation can be prevented with high safety.
[0012]
Moreover, it is preferable to set it as said muscle protein degradation inhibitor whose active ingredient amount with respect to an adult is 60 mg or more / day.
[0013]
Further, by using lycopene as an active ingredient in foods, cosmetics, pharmaceuticals, etc., it is possible to suppress muscle protein degradation without side effects.
[0014]
The inventors of the present application have found that knowing the amount of lycopene required during exercise and administering lycopene at an appropriate time is useful for strengthening muscles of elderly people and improving muscle fatigue of athletes. .
[0017]
DETAILED DESCRIPTION OF THE INVENTION
The lycopene used in the present invention is a kind of fat-soluble carotenoid (molecular weight 537) named as lycopene by CASchunk in 1903, and it does not change to vitamin A in the body like β-carotene. Although called, it has a strong antioxidant effect.
[0018]
A typical food containing a large amount of lycopene is tomato, and other than that, it is also contained in watermelon, strawberries, and ruby grapefruit. In addition, among the tomatoes, red tomatoes are particularly abundant. The content of lycopene varies greatly depending on the variety, but for example, cherry tomatoes have a knowledge of 7 to 11 mg per 100 g.
[0019]
Moreover, when making such lycopene act as a muscle protein degradation inhibitor, the amount of the active ingredient is used. As is clear from the experimental results described later, the results of genetically differing from the muscle tissue of the rat showed that muscle protein degradation can be suppressed by giving 10 mg or more of lycopene per day to a rat with a body weight of 280 g. It can also be applied to humans who do not.
[0020]
Although the behavior of rats and humans is different, it is presumed that humans are also effective at the same liver concentration as rats. Then, the lycopene concentration in the rat liver is 3.4 μg / ml and has an effect of inhibiting myoprotein degradation, and the lycopene concentration in the human liver is 4.4 times the serum concentration (Stahl et al. Archm. Biophys. , 297, 173-177), it is considered that the human serum concentration is 3.4 / 4.4 = 0.77 μg / ml and has an effect of inhibiting muscle protein degradation.
[0021]
Here, the normal human serum lycopene concentration is 100 to 200 ng / ml, and the intake for increasing the human serum lycopene concentration for the suppression of muscle protein degradation is 4 to 8 based on the results of the serum concentration increase test. Double the amount.
[0022]
Thus, the effective intake amount of a human (adult) calculated from the above view is approximately 60 mg / day or more.
[0023]
When exercising intensely, muscle protein degradation during exercise can be prevented by appropriately orally ingesting 60 mg or more of lycopene per day for healthy individuals. In addition, lycopene can be administered to foods, cosmetics, and pharmaceuticals to prevent muscle protein degradation.
[0024]
In addition, lycopene is known to be taken orally as a fat-soluble antioxidant provitamin contained in tomatoes and rice cakes, but in anticipation of this antioxidant effect, lycopene is ingested at a dose of 60 mg / day or more. It is effective in preventing muscle protein degradation.
[0025]
In addition, it is preferable from the viewpoint of absorption efficiency that the dosage and number of administrations of the muscular protein degradation inhibitor containing lycopene as an active ingredient should be divided into multiple doses if the above-mentioned effective dose per day can be taken. For example, it is more preferable to take each predetermined amount divided into 3 to 5 times.
[0026]
To prevent muscle damage by ingesting a muscle protein degradation inhibitor, take a muscle protein degradation inhibitor when the blood lycopene concentration is 100 to 200 ng / ml in the normal range and the test value is below this range. It is effective to do.
[0030]
In order to conduct a preventive test for muscle damage, not only the measurement of blood lycopene but also blood CPK, blood LDH, blood glucocorticoid, blood TNFα, urinary 3-methylhistidine (creatine ratio), muscle It is preferable to test glucocorticoid receptor content, muscle TNFα content, and muscle oxidation products (4HNE, TBARS, 8OHdG, etc.), especially these tests are necessary to check for muscle damage. is there.
[0031]
【Example】
As a method for examining the necessity and amount of lycopene during exercise, 9 weeks old SD female rats were preliminarily raised for 1 week, then the normal diet rest group, the normal diet exercise load group, and the lycopene exercise load group Divided into 3 groups.
[0032]
When lycopene was ingested, 50 mg of lycopene was mixed per 100 g of normal food and allowed to eat freely. The exercise load group was subjected to a relatively high intensity treadmill running exercise.
[0033]
The treadmill running exercise conditions were 15 m / min for 20 minutes without an inclination angle, and 20 minutes at 26 m / min for an inclination angle of 5 degrees, and the strength and exercise time were gradually increased for 2 weeks.
[0034]
Urine was collected for 24 hours after the final exercise was applied, and then sacrificed, and gastrocnemius muscle, liver and blood were collected.
<Examination of muscle protein degradation inhibitory effect>
The test items are the degree of muscle damage in serum CPK (creatine phosphokinase), the degree of liver function damage in serum GOT (glutamate oxaloacetate converting enzyme), the lipid oxidation state in serum lipid peroxide, and the degree of muscle protein degradation in urine 3- Methylhistidine (creatinine ratio), TNFα, and glucocorticoid receptor 1 were measured. In addition, lycopene concentrations in gastrocnemius and liver tissues were measured.
[0035]
[Table 1]
Figure 0004038088
[0036]
<Effects of lycopene intake during exercise>
CPK and GOT, which are muscle injury markers, were not observed in each exercise group as compared to resting. However, the urinary 3-methylhistidine or blood TNFα and blood glucocorticoid receptor 1 markers, which are markers for examining the degree of myoprotein degradation, had a lower value compared to the resting group. From these results, it was confirmed that lycopene was effective in inhibiting muscle protein degradation.
[0037]
In addition, from the above test results, when lycopene is added to food, it is effective in suppressing muscle protein degradation, and when lycopene is used as a raw material for cosmetics and pharmaceuticals, it has an effect of inhibiting muscle protein degradation. Is recognized.
[0038]
In addition, when lycopene is given at a dose of 10 mg or more per day for a 9-week-old rat body weight of 280 g, it can be applied to humans who have no genetic differences in muscle tissue. From the weight comparison, muscle protein degradation can be prevented by administering the required amount to lycopene-containing foods, cosmetics and pharmaceuticals.
[0039]
In other words, in all cases where intense exercise is performed, muscle protein degradation during exercise can be prevented by always ingesting 60 mg or more of lycopene per day for healthy individuals.
[0040]
Specifically, lycopene is a fat-soluble antioxidant provitamin contained in tomatoes and syrups, and is also drunk. However, when lycopene is taken as an active ingredient at 60 mg or more per day, muscle protein degradation can be prevented.
[0041]
When examining the presence or absence of muscle damage, blood CPK, blood LDH, blood glucocorticoid, blood TNFα, urinary 3-methylhistidine (creatine ratio), muscle glucocorticoid receptor content, muscle TNFα It was confirmed that the items of content and oxidation products in muscle (4HNE, TBARS, 8OHdG, etc.) were necessary.
[0042]
Referring to FIG. 1, first, 3-methylhistidine (creatine ratio = C) in urine is measured for a subject and compared with an S (= standard) value.
[0043]
The S (= standard) value is an average value of the creatine ratio measured from urine collected from many healthy subjects in advance. For example, 100 μmol of 3-methylhistidine and 1.0 g of creatinine were excreted in urine for 24 hours. Then, a value of 100 μmol / gr Cre / day can be adopted.
[0044]
Next, in the case of C ≦ S, it is recognized that no muscle damage has occurred, so that it is possible to determine to continue the muscle strengthening exercise as it is.
[0045]
On the other hand, if the result is C> S, muscle damage may have occurred, so the blood lycopene value is measured.
[0046]
To quantitatively measure blood lycopene, the following procedure was performed.
[0047]
First, after adding 1.0 ml of ethanol to 0.2 ml of serum, 5 ml of a mixed solvent of 4: 1 (volume ratio) of hexane and dichloromethane was added and stirred. After centrifuging this, the supernatant was taken out and the above steps were repeated once more.
[0048]
The obtained supernatant is concentrated under reduced pressure, dried and solidified, and 0.2 ml of solvent is added to dissolve it, and an ultraviolet or visible absorption detector (measurement wavelength: 460 nm, detection sensitivity: 20 ng / ml) or The blood lycopene value was measured by high performance liquid chromatogram method (HPLC analysis) using an electrochemical detector (detection sensitivity 0.1 ng / ml).
[0049]
When the blood lycopene value is a normal value (100 to 200 ng / ml), it is preferable to further measure the TNFα value and glucocorticoid receptor 1 to make a more precise determination. At this time, it is desirable to adjust the degree of strengthening exercise while watching the transition of urinary 3-methylhistidine and blood lycopene concentrations.
[0050]
If the blood lycopene level is lower than the normal level, nutritional guidance is given so that a large amount of lycopene-containing food (such as the above-mentioned tomatoes, watermelons, and strawberries) is ingested, and if necessary, the above-mentioned Ingestion of muscle protein degradation inhibitor.
[0051]
In this way, exercise and the degree of muscle protein degradation can be examined, a muscle protein degradation inhibitor can be ingested, or a product using food, cosmetics or pharmaceuticals containing lycopene or lycopene as an active ingredient can be used for health.
[0052]
In addition, when the muscle damage inspection method described above is implemented as a business system, the muscle protein degradation degree of a racehorse is examined with a muscle degradation marker, and if it shows an abnormal value, lycopene is added to the feed to prevent muscle destruction. be able to.
[0053]
In addition, by adding lycopene to the feed of cultured fish and measuring muscle degradation and lycopene concentration, it is possible to prevent muscle damage in advance, so it is possible to distribute delicious fish and deliver delicious fish to consumers. Is possible.
[0054]
As for muscle strengthening of the elderly, it can be expected to strengthen bones by exercising and to prevent osteoporosis and other bone metabolism abnormalities and prevent dementia and bedridden elderly people.
[0055]
【The invention's effect】
As described above, since the present invention is a muscle protein degradation inhibitor containing lycopene as an active ingredient, it acts directly and efficiently on muscle protein degradation in humans and other animals and has no side effects. There is an advantage that it is a decomposition inhibitor.
[0057]
In addition, when it is determined that the blood lycopene concentration is less than this range with a predetermined range of blood lycopene concentration, the muscle protein is not damaged by grasping the health condition of the muscle and ingesting the muscle protein degradation inhibitor. Can maintain good health.
[Brief description of the drawings]
FIG. 1 is a flowchart for explaining an embodiment of a method for preventing muscle damage.

Claims (3)

リコピンを、筋蛋白分解予防の有効成分として含有する筋蛋白分解抑制剤。  A muscle protein degradation inhibitor containing lycopene as an active ingredient for preventing muscle protein degradation. 有効成分が、一日摂取量として60mg以上含有するよう製剤されている請求項1に記載の筋蛋白分解抑制剤。  The muscle protein degradation inhibitor according to claim 1, wherein the active ingredient is formulated so as to contain 60 mg or more as a daily intake. リコピンを、尿中の3−メチルヒスチジンの抑制、血中TNFαの産生抑制または血中グルココルチコイドレセプターの抑制に有効な成分として含有する請求項1または請求項2に記載の筋蛋白分解抑制剤。  The muscle protein degradation inhibitor according to claim 1 or 2, which contains lycopene as an effective component for inhibiting 3-methylhistidine in urine, inhibiting production of blood TNFα, or inhibiting blood glucocorticoid receptor.
JP2002221242A 2002-07-30 2002-07-30 Muscle protein degradation inhibitor Expired - Fee Related JP4038088B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2002221242A JP4038088B2 (en) 2002-07-30 2002-07-30 Muscle protein degradation inhibitor

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2002221242A JP4038088B2 (en) 2002-07-30 2002-07-30 Muscle protein degradation inhibitor

Publications (2)

Publication Number Publication Date
JP2004059518A JP2004059518A (en) 2004-02-26
JP4038088B2 true JP4038088B2 (en) 2008-01-23

Family

ID=31941614

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002221242A Expired - Fee Related JP4038088B2 (en) 2002-07-30 2002-07-30 Muscle protein degradation inhibitor

Country Status (1)

Country Link
JP (1) JP4038088B2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101296693B (en) 2005-10-26 2012-07-04 花王株式会社 Endurance improver
US8962678B2 (en) 2006-07-05 2015-02-24 Kao Corporation Senescence inhibitor
US20100047374A1 (en) 2007-01-16 2010-02-25 Rena Sakakibara Composition for protecting muscle damage
US20090118227A1 (en) 2007-11-07 2009-05-07 Bristol-Myers Squibb Company Carotenoid-containing compositions and methods
JP6395350B2 (en) 2013-03-28 2018-09-26 雪印メグミルク株式会社 Muscle atrophy prevention agent

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998033494A1 (en) * 1997-02-04 1998-08-06 Kosbab John V Compositions and methods for prevention and treatment of vascular degenerative diseases
DE19838636A1 (en) * 1998-08-26 2000-03-02 Basf Ag Carotenoid formulations containing a mixture of beta-carotene, lycopene and lutein
DE19841930A1 (en) * 1998-09-14 2000-03-16 Basf Ag Stable, powdery lycopene formulations containing lycopene with a degree of crystallinity greater than 20%
FR2792831B1 (en) * 1999-04-28 2001-08-03 Bionatec Sarl COMPOSITION FOR COSMETIC AND / OR DIETETIC USE COMPRISING A MIXTURE OF LYCOPENE AND OLIVE LEAF EXTRACT
JP2002017295A (en) * 2000-07-05 2002-01-22 Yamagami Suehito Health auxiliary food product having activity for ameliorating eye disease and activity for keeping function of eye
JP2002125619A (en) * 2000-10-31 2002-05-08 Kikkoman Corp Lycopene composition, method of producing the same and use thereof

Also Published As

Publication number Publication date
JP2004059518A (en) 2004-02-26

Similar Documents

Publication Publication Date Title
EP1773364B1 (en) Nutritional compositions and methods for treating or preventing osteoporosis
US9446006B2 (en) Hydroxytyrosol combinations for enhancing mitochondrial function and energy production
RU2356247C2 (en) Combinations and compositions containing fatty acids and amino acids, their application for prevention and delay of progressing or treatment of diabetes and diabetes associated diseases and conditions, method of weight reduction in mammal, kit
EP2869717B1 (en) Prevention of alcohol reaction with dietary supplements
US7435431B2 (en) Method for controlling body weight in estrogen-insufficient women
US11547736B2 (en) Sauvignon blanc grape seed products for nonalcoholic fatty liver disease
WO2012097064A1 (en) Nutritional compositions and methods for controlling blood glucose
WO2012097061A1 (en) Nutritional compositions and methods for improving skeletal muscle protein metabolism
US20130330431A1 (en) Olive juice extracts for promoting muscle health
JP2010524876A (en) Use of hydroxytyrosol as an anti-aging agent
EP2884970A1 (en) Methods and compositions useful for improving bone and joint health
EP2052729B1 (en) Antiobesity composition containing component originating in the bark of tree belonging to the genus acacia
JP4038088B2 (en) Muscle protein degradation inhibitor
KR101574536B1 (en) Composition for promoting growth comprising coumaric acid
US7601370B2 (en) Method for controlling body weight in estrogen-insufficient women
WO2014143192A1 (en) Reduction or prevention of alcohol reaction with dietary supplements
Hecht et al. Astaxanthin for improved muscle function and enhanced physical performance
WO2023022174A1 (en) Food composition for suppressing muscle fatigue and/or sudden muscle pain
Kaur et al. Nutritional integrative approaches for the management of sarcopenia.
JP2022169385A (en) Lipid metabolism improver containing pleurotus citrinopileatus or processed product thereof as active ingredient
AU2011265567A1 (en) Nutritional compositions and methods for treating or preventing osteoporosis

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20060829

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20061030

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20070605

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070806

A911 Transfer of reconsideration by examiner before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20070918

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20071016

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20071102

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20101109

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20111109

Year of fee payment: 4

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20111109

Year of fee payment: 4

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20121109

Year of fee payment: 5

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20131109

Year of fee payment: 6

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees